Stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy
AssigneeDiagen D.O.O.
InventorRudolf Rucman
Life of this patent
Estimating the term…
Abstract
Stable pentadecapeptide salts of formula (I): (I) SEQ ID NO 1 Gly Glu Pro Pro Pro Gly Lys Pro Ala Asp Asp Ala 1 5 10 Gly Leu Val · n BAA 15 wherein n means 1, 2 or 3, and BAA means basic amino acid, a process for the preparation thereof, a process for the use thereof for the manufacture of pharmaceutical formulations in liquid and solid form and a use thereof for prevention, protection in treatment of diseases and disease conditions and for the preparation of formulations for use as food supplements are described.
Claims33
A stable pentadecapeptide salt comprising formula (I), wherein formula (I) is:
- SEQ ID NO:
- 1·2 BAA
- wherein BAA represents a basic amino acid.
A process for the preparation of a stable pentadecapeptide salt comprising formula (I), wherein formula (I) is:
- SEQ ID NO:
- 1·2 BAA
- wherein BAA represents a basic amino acid,
- comprising reaction of pentadecapeptide according to SEQ ID NO:
- 1 with basic amino acid under stirring of the solution, adjusting pH value and isolation of the salt formed by high performance liquid chromatography and lyophilisation of the solution.
A method for prevention, protection and treatment of at least one of a plurality of diseases, disease conditions or disorders, comprising administering to an individual in need of such treatment therapeutically effective amount of a stable pentadecapeptide salt comprising formula (I), wherein formula (I) is:
- SEQ ID NO:
- 1·2 BAA
- wherein BAA represents a basic amino acid, and
- wherein the at least one of the plurality of diseases, disease conditions or disorders is one from the group consisting of:
- stress related diseases and disorders,
- ulcers in any part of gastrointestinal tract, generally antiinflammatory activity, gastrointestinal inflammatory disease, Crohn's disease and acute pancreatitis,
- diseases, disease conditions or disorders in need of organoprotective activity,
- viral infections comprising hepatitis A, herpes strains, influenza A and arthropode borne (ARBO) viruses, the ARBO viruses comprising tick borne encephalitis, West Nile fever, dengue types 1-4, cytomegalovirus (CMV) and lymphocytic choriomeningitis (LCM) virus, and feline leukemia virus,
- melanoma and related tumors,
- accelerated healing of wounds, burns, bone fractures, regeneration of ruptured nerve linkages, Achiles' tendon and ruptured muscles, spinal cord injury,
- organic disorders associated with nitric oxide (NO) formation:
- hypertension, hypotension, anaphylaxis, circulatory and septic shock, aggregation of thrombocytes,
- neurological diseases and disorders:
- multiple sclerosis, myasthenia gravis, lupus erythematosus, neuropathy, dysfunction of somatosensory nerves, asthma, rhinitis, pemphigus and eczema,
- catecholaminergic dysfunction, schizophrenia, amphetamine, drug and alcohol withdrawal effects,
- disorders due to corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs),
- squamous degeneration of macula in eyes,
- rapid reorganisation of blood supply is mandatory,
- gain weight increment in animals and wherein the individual is an animal,
- an increase in sperm stability in storage and wherein the individual is an animal, and
- hepatic and pancreatic lesions.
Dependencies are inferred from the claim text.